Are we there yet? cellular therapies for cutaneous T cell lymphoma

IF 3.2 4区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Current Research in Translational Medicine Pub Date : 2023-04-01 DOI:10.1016/j.retram.2023.103390

Pinar Ataca Atilla , Erden Atilla

{"title":"Are we there yet? cellular therapies for cutaneous T cell lymphoma","authors":"Pinar Ataca Atilla , Erden Atilla","doi":"10.1016/j.retram.2023.103390","DOIUrl":null,"url":null,"abstract":"<div>Cutaneous T cell lymphomas (CTCLs) are a heterogenous group of skin-involved T-cell non-Hodgkin lymphoma which Mycosis Fungoides and Sezary Syndrome are the most common variants. Despite considerable progress in distinguishing the pathophysiology, the treatment options are still limited for advanced-stage disease. Recent approval of novel agents such as vorinostat, brentuximab vedotin and mogamulizumab paved a way. Allogeneic hematopoietic stem cell transplantation has been shown to be a feasible option in selected advanced-stage CTCL patients. Chimeric antigen receptor (CAR) T cells have been promising for the treatment of B-cell tumors and have been approved for second-line treatment in non-Hodgkin's lymphoma. Although several obstacles still need to be addressed, CAR T cell treatment for CTCLs seems not far off. This review discusses new discoveries in pathophysiology, the state of cellular therapies in current practice, challenges for cellular treatment in advanced CTCL, and how to overcome these challenges.</div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 2","pages":"Article 103390"},"PeriodicalIF":3.2000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452318623000144","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 2

Abstract

Cutaneous T cell lymphomas (CTCLs) are a heterogenous group of skin-involved T-cell non-Hodgkin lymphoma which Mycosis Fungoides and Sezary Syndrome are the most common variants. Despite considerable progress in distinguishing the pathophysiology, the treatment options are still limited for advanced-stage disease. Recent approval of novel agents such as vorinostat, brentuximab vedotin and mogamulizumab paved a way. Allogeneic hematopoietic stem cell transplantation has been shown to be a feasible option in selected advanced-stage CTCL patients. Chimeric antigen receptor (CAR) T cells have been promising for the treatment of B-cell tumors and have been approved for second-line treatment in non-Hodgkin's lymphoma. Although several obstacles still need to be addressed, CAR T cell treatment for CTCLs seems not far off. This review discusses new discoveries in pathophysiology, the state of cellular therapies in current practice, challenges for cellular treatment in advanced CTCL, and how to overcome these challenges.

查看原文本刊更多论文

我们到了吗？皮肤T细胞淋巴瘤的细胞治疗

皮肤T细胞淋巴瘤（CTCLs）是一组异质性的皮肤相关T细胞非霍奇金淋巴瘤，其中真菌样肉芽肿和Sezary综合征是最常见的变体。尽管在区分病理生理学方面取得了相当大的进展，但晚期疾病的治疗选择仍然有限。最近批准的新型制剂，如伏立诺司他、布伦妥昔单抗-韦多汀和莫加穆利珠单抗，铺平了道路。异基因造血干细胞移植已被证明是选择晚期CTCL患者的可行选择。嵌合抗原受体（CAR）T细胞已被看好用于治疗B细胞肿瘤，并已被批准用于非霍奇金淋巴瘤的二线治疗。尽管仍有几个障碍需要解决，但CAR T细胞治疗CTCL似乎并不遥远。这篇综述讨论了病理生理学的新发现、当前实践中细胞疗法的现状、晚期CTCL细胞治疗的挑战，以及如何克服这些挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Research in Translational Medicine Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology

CiteScore

7.00

自引率

4.90%

发文量

审稿时长

45 days

期刊介绍： Current Research in Translational Medicine is a peer-reviewed journal, publishing worldwide clinical and basic research in the field of hematology, immunology, infectiology, hematopoietic cell transplantation, and cellular and gene therapy. The journal considers for publication English-language editorials, original articles, reviews, and short reports including case-reports. Contributions are intended to draw attention to experimental medicine and translational research. Current Research in Translational Medicine periodically publishes thematic issues and is indexed in all major international databases (2017 Impact Factor is 1.9). Core areas covered in Current Research in Translational Medicine are: Hematology, Immunology, Infectiology, Hematopoietic, Cell Transplantation, Cellular and Gene Therapy.